| Title |
A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study
|
|---|---|
| Published in |
BMC Pulmonary Medicine, November 2014
|
| DOI | 10.1186/1471-2466-14-176 |
| Pubmed ID | |
| Authors |
Dave Singh, Helena Pujol, Anna Ribera, Beatriz Seoane, Eric Massana, Carol Astbury, Sandrine Ruiz, Gonzalo de Miquel |
| Abstract |
Long-acting beta2-adrenergic agonists (LABAs) are recommended in combination with inhaled corticosteroids (ICSs) for asthma management. Abediterol is a novel, selective, potent, once-daily LABA in development for treatment of asthma and chronic obstructive pulmonary disease. This study aimed to determine abediterol doses with similar peak bronchodilatory effect to salbutamol 400 mug, and duration of action compatible with once-daily dosing in patients with persistent, stable asthma. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 30 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 4 | 13% |
| Other | 4 | 13% |
| Researcher | 3 | 10% |
| Unspecified | 2 | 7% |
| Librarian | 1 | 3% |
| Other | 4 | 13% |
| Unknown | 12 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 27% |
| Nursing and Health Professions | 3 | 10% |
| Unspecified | 2 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Computer Science | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 13 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 August 2015.
All research outputs
#14,789,596
of 22,770,070 outputs
Outputs from BMC Pulmonary Medicine
#957
of 1,905 outputs
Outputs of similar age
#142,604
of 258,049 outputs
Outputs of similar age from BMC Pulmonary Medicine
#25
of 40 outputs
Altmetric has tracked 22,770,070 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,905 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 258,049 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.